| 251 |
10215647 | Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. | 1999 May |
2 |
| 252 |
10377455 | Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. | 1999 Jun 22 |
1 |
| 253 |
10383505 | Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. | 1999 Jun |
1 |
| 254 |
10391112 | Clinical experience with cyclooxygenase-2 inhibitors. | 1999 May |
1 |
| 255 |
10391671 | Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humans. | 1999 Jun |
2 |
| 256 |
10406640 | The discovery of rofecoxib, [MK 966, Vioxx, 4-(4'-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2-inhibitor. | 1999 Jul 5 |
3 |
| 257 |
10411562 | Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. | 1999 Aug |
7 |
| 258 |
10414247 | [Specific inhibitors of cyclo-oxygenase-2: a revolution?]. | 1999 Jun 19 |
1 |
| 259 |
10500058 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. | 1999 Oct |
1 |
| 260 |
10566565 | The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. | 1999 Oct |
1 |
| 261 |
10580458 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. | 1999 Nov 24 |
1 |
| 262 |
10692773 | Novel nonsteroidal anti-inflammatory drugs. | 1999 Oct-Dec |
1 |